The Burden of Human African Trypanosomiasis

  • A. Shaw
  • J. Robays
  • E. M. Fèvre
  • P. Lutumba
  • M. Boelaert


 Human African Trypanosomiasis (HAT), a once largely forgotten disease, is back on the agenda. A public-private partnership between the World Health Organization (WHO), pharmaceutical companies and international donors succeeded in curbing the recent epidemic, but active transmission is still ongoing in several countries. The burden of the disease in affected individuals is high. Untreated the disease is always fatal and estimates of the Disability Adjusted Life Years (DALYs) lost per premature death range from 25 to 33 years. Even for successfully treated patients, the burden on households and livelihoods is high – between 1.5 and 10 months’ income, even when diagnostics and HAT drugs are provided for free. Costs ranging from $10–17 per DALY averted for case-finding and treatment places the control of T.b. gambiense HAT firmly in the category of highly cost-effective health interventions.


Active Screening Human African Trypanosomiasis Bilateral Donor Screening Campaign Unreported Case 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

List of Abbreviations:


disability adjusted life year


democratic republic of Congo


Human African Trypanosomiasis


Non-Governmental Organization


  Trypanosoma brucei


World Health Organization


years of life lost


  1. Fèvre EM, Odiit M, Coleman PG, Woolhouse ME, Welburn SC. (2008). BMC Public Health. 8: 96.PubMedCrossRefGoogle Scholar
  2. Fèvre EM, Picozzi K, Fyfe J, Waiswa C, Odiit M, Coleman PG, Welburn SC. (2005). Lancet. 366: 745–747.PubMedCrossRefGoogle Scholar
  3. Goodwin C, Coleman P, Mills A. (2000). Economic Analysis of Malaria Control in Sub-Saharan Africa. Global Forum for Health Research, Geneva, Switzerland.Google Scholar
  4. Gouteux JP, Bansimba P, Noireau F, Frézil JL (1987). Med Trop. 47: 61–63.Google Scholar
  5. Gouteux JP, Sinda D. (1990). Trop Med Parasitol. 41: 49–55.PubMedGoogle Scholar
  6. Lancien J. (1991). Ann Soc Belg Méd Trop. 71 (Suppl. 1): 35–47.PubMedGoogle Scholar
  7. Laveissiére C, Grébaut P, Lemasson J. (1994). Les communautés rurales et la lutte contre la maladie du sommeil en forêt de Côte-d’Ivoire, WHO/TRY/94.1, Genève.Google Scholar
  8. Lutumba P, Makieya E, Shaw A, Meheus F, Boelaert M. (2007a). Emerg Infect Dis. 13: 248–254.PubMedCrossRefGoogle Scholar
  9. Lutumba P, Meheus F, Robays J, Miaka C, Kande V, Buscher P, Dujardin B, Boelaert M. (2007b). Emerg Infect Dis. 13: 1484–1490.PubMedCrossRefGoogle Scholar
  10. Lutumba P, Robays J, Miaka mia BC, Mesu VK, Molisho D, Declercq J, Van der Veken W, Meheus F, Jannin J, Boelaert M. (2005). Emerg Infect Dis. 11: 1382–1389.PubMedGoogle Scholar
  11. Moore A, Richer M. (2001). Trop Med Int Health. 6: 342–347.PubMedCrossRefGoogle Scholar
  12. Moore A, Richer M, Enrile M, Losio E, Roberts J, Levy D. (1999). Am J Trop Med Hyg. 61: 315–318.PubMedGoogle Scholar
  13. Odiit M. (2003). The Epidemiology of Trypanosoma brucei rhodesiense in Eastern Uganda. Unpublished PhD thesis, University of Edinburgh, pp. 210.Google Scholar
  14. Odiit M, Coleman PG, Liu WC, McDermott JJ, Fèvre EM, Welburn SC, Woolhouse ME. (2005). Trop Med. Int Health. 10: 840–849.PubMedCrossRefGoogle Scholar
  15. Odiit M, Shaw A, Welburn SC, Fèvre EM, Coleman PG, McDermott JJ. (2004). Ann Trop Med Parasitol. 98: 339–348.PubMedCrossRefGoogle Scholar
  16. Politi C, Carrin G, Evans D, Kuzoe FA, Cattand PD. (1995). Health Econ. 4: 273–287.PubMedGoogle Scholar
  17. Priotto G, Pinoges L, Fursa IB, Burke B, Nicolay N, Grillet G, Hewison C, Balasegaram M. (2008). BMJ. 336: 705–708.PubMedCrossRefGoogle Scholar
  18. Robays J, Bilengue MM, Van der SP, Boelaert M. (2004). Trop Med Int Health. 9: 542–550.PubMedCrossRefGoogle Scholar
  19. Robays J, Raguenaud ME, Josenando T, Boelaert M. (2008). Trop Med Int Health. Feb; 13(2): 265–271.Google Scholar
  20. Schmid C, Shaw A, Santercole C, Kwete J, Lutumba P, Burri C. (2004). In: Schmid C. (2004) 10-Day Melarsoprol Treatment of Trypanosoma brucei gambiense Sleeping Sickness. PhD Thesis, University of Basel. Basler Schnelldruck, Basel.Google Scholar
  21. Shaw AP. (1989). Ann Soc Belg Med Trop. 69 (Suppl. 1): 237–253.PubMedGoogle Scholar
  22. Shaw AP, Cattand P. (2001). Med Trop (Mars). 61: 412–421.Google Scholar
  23. Shaw APM. (2004). In: Maudlin I, Holmes PH, Miles MA (eds.). The Trypanosomiases. CAB International, Wallingford, UK, pp. 369–402.CrossRefGoogle Scholar
  24. Simarro PP, Sima FO, Mir M, Mateo MJ, Roche J. (1991). Bull World Health Organ. 69: 451–457.PubMedGoogle Scholar
  25. Trowbridge M, McFarland D, Richer M, Adeoye M, Moore A. (2001). Am J Trop Med Hyg. 62 (3 Suppl.): 312.Google Scholar
  26. Van Nieuwenhove S, Betu-Ku-Mesu VK, Diabakana PM, Declercq J, Bilengé CM. (2001). Trop Med Int Health. 6: 335–341.PubMedCrossRefGoogle Scholar
  27. Welburn SC, Fèvre EM, Coleman PG, Odiit M, Maudlin I. (2001). Trends Parasitol. 17: 19–24.PubMedCrossRefGoogle Scholar
  28. WHO. (1998). World Health Organ Tech. Rep. Ser. 881: I-114.Google Scholar
  29. WHO. (2000) WHO Report on Global Surveillance of Epidemic-prone Infectious Diseases. WHO Department of Communicable Disease Surveillance and Response, WHO/CDS/CSR/ISR/2000.1.Google Scholar
  30. WHO. (2004) Wkly Epidemiol Rec. 79: 297–300.Google Scholar
  31. WHO. (2006) Wkly Epidemiol Rec. 81: 71–80.Google Scholar

Copyright information

© Springer Science+Business Media LLC 2010

Authors and Affiliations

  • A. Shaw
    • 1
  • J. Robays
  • E. M. Fèvre
    • 2
  • P. Lutumba
  • M. Boelaert
  1. 1.AP ConsultantsHampshireUK
  2. 2.Ashworth Laboratories Centre for Infectious DiseasesUniversity of EdinburghEdinburghUnited Kingdom

Personalised recommendations